Abstract
In considering the impact of blood-pressure variability on health outcomes, two methodological challenges arise: The presence of multiple timescales of variability that may act independently and interactively, and the fairly large stochastic uncertainty that is inevitable in estimates of individual variability based on modest numbers of observations. Here we present an application of Bayesian hierarchical modeling to the problem of estimating the effect of blood pressure (BP) variability on all-cause and cardiovascular mortality with two timescales – short-term variation among multiple measures at one visit, and medium-term variation between the measures at two visits several months apart. We use data from the Third National Health and Nutrition Examination Survey linked with up to 27 years of mortality follow-up. We find that medium-term systolic BP variability had a very significant predictive value for CV and all-cause mortality, around one-third as large as the well-established impact of mean systolic BP. Medium-term diastolic variability had an additional, though smaller, predictive effect. Short-term variability, on the other hand, had little or no measurable predictive value. The medium-term variability effect persisted when controlling for Framingham risk score.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Biotechnology and Biological Sciences Research Council (BBSRC) under the grant number BB/S001824/1
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Authors for communication: David Steinsaltz, Hamish Patten and David H. Rehkopf
Data Availability
All data produced are available online at https://www.cdc.gov/nchs/nhanes/index.htm
